ESMO26: Vincent Xu, MD on KIM1 in Kidney Cancer | Dana-Farber Cancer Institute
RCC Content Hub
Research at #ESMO26, presented by Vincent (Wenxin) Xu, MD, of Dana-Farber Cancer Institute,
shows among patients with advanced kidney cancer on immunotherapy alone, KIM-1 reductions were seen in immune-inflamed tumors, while no KIM-1 drop was linked to immune-depleted tumors.
Video published Oct 30, 2026